The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

President - Merck Research Laboratories; Merck & Co Inc Thank you for standing by. Welcome to the Merck and Company Q4 sales and earnings conference call. (Operator Instructions) This call is being ...

Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dr. Dean Li, president of Merck Research Labs. Before we get ...

The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ...

Dr. Dean Li, President, Merck Research Laboratories, would no doubt disagree. In a webcast to analysts, Li noted that in 2024 more than 20 Phase 3 studies were initiated in multiple therapeutic areas.

(RTTNews) - Merck & Co Inc. (MRK), Thursday said it has decided to stop the Phase 3 HYPERION study evaluating Winrevair in pulmonary arterial hypertension (PAH). The HYPERION study is designed to ...

Merck Foundation and First Ladies of Africa mark World Cancer Day 2025: 194 Oncology Scholarships Provided Across 32 African Countries ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Merck Research Laboratories. "This positive opinion is yet another testament to the clinical profile of CAPVAXIVE and brings us a step closer to helping protect adults in the EU against ...